Clicky

Editas Medicine, Inc.(EDIT)

Description: As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases


Keywords: Biotechnology Biology Immune System Enzymes Genetics Genetic Engineering DNA Genome CRISPR Genome Editing Cas9

Home Page: www.editasmedicine.com

EDIT Technical Analysis

11 Hurley Street
Cambridge, MA 02141
United States
Phone: 617 401 9000


Officers

Name Title
Mr. James C. Mullen Exec. Chairman
Ms. Michelle Robertson CFO, Principal Accounting Officer, Treasurer & Assistant Sec.
Dr. Mark S. Shearman Exec. VP & Chief Scientific Officer
Dr. Bruce E. Eaton Ph.D. Exec. VP & Chief Bus. Officer
Dr. Gilmore O'Neill Pres & CEO
Dr. Feng Zhang Ph.D. Co-Founder & Scientific Advisory Board Member
Dr. George McDonald Church Ph.D. Co-Founder & Scientific Advisory Board Member
Dr. J. Keith Joung M.D., Ph.D. Co-Founder & Scientific Advisory Board Member
Dr. David R. Liu Ph.D. Co-Founder & Scientific Advisory Board Member
Mr. Harry R. Gill III Sr. VP of Operations

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 1.7176
Price-to-Sales TTM: 26.3844
IPO Date: 2016-02-03
Fiscal Year End: December
Full Time Employees: 264
Back to stocks